<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460719</url>
  </required_header>
  <id_info>
    <org_study_id>V212-013</org_study_id>
    <nct_id>NCT01460719</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With HM Receiving Treatment With Anti-CD20 Monoclonal Antibodies (V212-013)</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multicenter study to evaluate the safety and immunogenicity of inactivated
      Varicella-Zoster Virus (V212) vaccine in participants with hematologic malignancies (HM) who
      are currently receiving anti-CD20 monoclonal antibodies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2012</start_date>
  <completion_date type="Actual">September 25, 2012</completion_date>
  <primary_completion_date type="Actual">September 25, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Foldrise (GMFR) of the VZV-specific Immune Responses measured by VZV Interferon-gamma (IFN-g) ELISPOT</measure>
    <time_frame>Prevaccination to ~28 days Postdose 4</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>V212 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212</intervention_name>
    <description>V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.</description>
    <arm_group_label>V212 Arm</arm_group_label>
    <other_name>Inactivated Varicella-Zoster (VZV) vaccine</other_name>
    <other_name>Zostavax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a HM and is receiving treatment with anti-CD20 monoclonal antibodies
             and is not likely to undergo hematopoietic cell transplant (HCT).

          -  Has a predicted life expectancy of â‰¥ 12 months.

          -  Has prior history of varicella or antibodies to VZV due to exposure to the disease in
             a country where the disease is common.

          -  All female participants of childbearing potential must have a negative serum or urine
             pregnancy test.

        Exclusion Criteria:

          -  A history of allergic reaction to any vaccine component (including gelatin) or an
             anaphylactic/anaphylactoid reaction to neomycin.

          -  Prior history of HZ within 1 year of enrollment.

          -  Prior receipt of any varicella or zoster vaccine.

          -  Participant is pregnant or breastfeeding or expecting to conceive within the period of
             2 weeks prior to enrollment throughout 6 months after last vaccination dose.

          -  Any live virus vaccine administered or scheduled in the period from 4 weeks prior to
             Dose 1 through 28 days postvaccination dose 4.

          -  Any inactivated vaccine administered or scheduled within the period from 7 days prior
             to, through 7 days following, any dose of study vaccine.

          -  Participant is currently participating or has participated in a study with an
             investigational anti-CD20 monoclonal antibody within 3 months of signing informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, Zhao Y, Chan IS, Kaplan SS. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 2017 Mar 27;35(14):1764-1769. doi: 10.1016/j.vaccine.2016.10.055. Epub 2017 Mar 3.</citation>
    <PMID>28268074</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

